CVT begins second regadenoson study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics has initiated a second cardiac perfusion imaging trial of its pharmacologic stress agent regadenoson (CVT-3146), the firm announces April 26. CVT and partner Fujisawa plan to submit an NDA "as quickly as possible." CVT is highlighting a potential safety benefit via regadenoson's selectivity for the A2A-adenosine receptor, responsible for coronary vasodilation. The first Phase III trial started in October 2003...
You may also be interested in...
CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006
CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission
Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.
Executives On The Move: Genmab Promotes New CMO, BiondVax And Sprint Bioscience Pick Up New CEOs
Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: